Meeting
2020 ASCO Virtual Scientific Program
Impact of SWI/SNF complex mutations in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors: Immuno-oncology biomarker study in LC-SCRUM-Japan (LC-SCRUM-IBIS).
Authors
Kiyotaka Yoh
National Cancer Center Hospital East, Kashiwa, Japan
Kiyotaka Yoh , Shingo Matsumoto , Naoki Furuya , Kazumi Nishino , Shingo Miyamoto , Satoshi Oizumi , Norio Okamoto , Hidetoshi Itani , Shoichi Kuyama , Atsushi Nakamura , Yuichiro Hayashi , Noriko Motoi , Genichiro Ishii , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9530)
DOI
10.1200/JCO.2020.38.15_suppl.9530
Abstract #
9530
Poster Bd #
296
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: Assessment of PD-L1 expression and tumor mutation burden in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
First Author: Kiyotaka Yoh
Poster
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
First Author: Alessio Cortellini
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang
Poster
2019 ASCO Annual Meeting
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
First Author: Kiyotaka Yoh